Electromed, Inc. (ELMD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Electromed, Inc. (ELMD) Healthcare & Pipeline Overview

Electromed, Inc. develops and markets airway clearance therapy solutions, notably the SmartVest system utilizing HFCWO technology. Targeting the home healthcare market for patients with respiratory conditions like bronchiectasis and cystic fibrosis, Electromed distinguishes itself through its focus on patient-centric design and connectivity features.

What Is the Investment Thesis for ELMD?

Electromed, Inc. presents a focused investment opportunity within the medical device sector, specifically in airway clearance therapy. The company's consistent profitability, demonstrated by a 13.1% profit margin, and high gross margin of 78.2% indicate efficient operations. Growth is expected to be driven by increasing awareness and adoption of HFCWO therapy for chronic respiratory conditions. Key catalysts include the expansion of the SmartVest Connect platform and potential partnerships to broaden market reach. However, investors may want to evaluate the risks associated with competition and reimbursement pressures within the medical device industry. The company's beta of 0.32 suggests lower volatility compared to the overall market.

Based on FMP financials and quantitative analysis

ELMD Key Highlights

Market capitalization of $327M reflects Electromed's current valuation in the medical device market.

• P/E ratio of 23.5 indicates investor expectations for future earnings growth relative to its current price.
• Gross margin of 78.2% highlights Electromed's ability to maintain high profitability on its products.
• Profit margin of 13.1% demonstrates effective cost management and operational efficiency.
• Beta of 0.32 suggests the stock is less volatile than the overall market, potentially offering stability to investors.

Who Are ELMD's Competitors?

ELMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ELMD's Key Strengths?

Proprietary HFCWO technology.

• Established brand recognition.
• High gross margin.
• SmartVest Connect platform.

What Are ELMD's Weaknesses?

Limited product portfolio.

• Reliance on the U.S. market.
• Smaller market capitalization compared to competitors.
• No dividend payout.

What Could Drive ELMD Stock Higher?

Expansion of SmartVest Connect platform to include additional features and integrations.

• Increasing awareness and adoption of HFCWO therapy for bronchiectasis.
• Strategic partnerships with healthcare providers to expand market reach.

What Are the Key Risks for ELMD?

Competition from larger medical device companies with greater resources.

• Reimbursement pressures from healthcare payers impacting pricing and profitability.
• Technological advancements by competitors leading to alternative airway clearance therapies.
• Regulatory changes in the medical device industry affecting product approvals and market access.

What Are the Growth Opportunities for ELMD?

• Expansion of SmartVest Connect Platform: Electromed can leverage its SmartVest Connect platform to enhance patient engagement and therapy adherence. By providing personalized therapy management and remote monitoring capabilities, the company can improve patient outcomes and drive adoption of its SmartVest system. The market for connected medical devices is rapidly growing, with a projected market size of $63.5 billion by 2027, offering a significant opportunity for Electromed to expand its reach and market share.
• Strategic Partnerships with Healthcare Providers: Electromed can pursue strategic partnerships with hospitals, clinics, and home healthcare agencies to increase awareness and adoption of its HFCWO therapy. By collaborating with healthcare providers, the company can gain access to a wider patient base and integrate its SmartVest system into standard care protocols. Such partnerships can also facilitate reimbursement and streamline the prescription process, driving revenue growth.
• Geographic Expansion into International Markets: Electromed has the opportunity to expand its presence in international markets, where the prevalence of chronic respiratory diseases is increasing. By targeting specific regions with high unmet needs for airway clearance therapy, the company can diversify its revenue streams and reduce its reliance on the U.S. market. Market research and regulatory approvals will be critical for successful international expansion.
• Development of New Airway Clearance Products: Electromed can invest in research and development to create new and innovative airway clearance products that address unmet needs in the respiratory care market. This could include developing smaller, more portable HFCWO devices or exploring alternative airway clearance technologies. By expanding its product portfolio, the company can attract new customers and strengthen its competitive position.
• Increased Focus on Direct-to-Patient Marketing: Electromed can enhance its direct-to-patient marketing efforts to raise awareness of its SmartVest system and its benefits for individuals with chronic respiratory conditions. By leveraging digital marketing channels, social media, and patient advocacy groups, the company can reach a wider audience and drive demand for its products. This approach can empower patients to take control of their respiratory health and seek out effective airway clearance therapies.

What Are ELMD's Competitive Advantages?

• Proprietary HFCWO technology in the SmartVest system.
• Established brand reputation in the airway clearance therapy market.
• Strong relationships with physicians and healthcare providers.
• SmartVest Connect platform provides a competitive edge through personalized therapy management.

What Does ELMD Do?

Electromed, Inc., founded in 1992 and headquartered in New Prague, Minnesota, is a medical device company focused on developing, manufacturing, and marketing innovative airway clearance therapies. The company's core product is the SmartVest Airway Clearance System, which utilizes High Frequency Chest Wall Oscillation (HFCWO) technology to help patients mobilize and clear secretions from their lungs. This therapy is particularly beneficial for individuals with chronic respiratory conditions such as bronchiectasis, cystic fibrosis, and neuromuscular diseases. The SmartVest system includes an inflatable therapy garment, an air pulse generator, and a single-hose connection. Electromed has continued to innovate with the SmartVest SQL System and SmartVest Connect, a wireless technology that provides personalized therapy management. In addition to its home healthcare focus, Electromed offers single-patient-use SmartVest and SmartVest Wrap products for acute care settings. The company markets its products directly to patients and through physicians and healthcare providers, both domestically and internationally. Electromed's commitment to improving the quality of life for patients with respiratory conditions has solidified its position in the airway clearance therapy market.

What Products and Services Does ELMD Offer?

• Develops and manufactures the SmartVest Airway Clearance System.
• Offers High Frequency Chest Wall Oscillation (HFCWO) therapy.
• Provides solutions for patients with chronic respiratory conditions.
• Markets products to physicians, healthcare providers, and patients.
• Offers SmartVest Connect, a wireless therapy management portal.
• Provides single-patient-use SmartVest products for acute care.

How Does ELMD Make Money?

• Sells SmartVest Airway Clearance Systems to home healthcare market.
• Generates revenue through direct sales to patients and healthcare providers.
• Offers SmartVest Connect subscription for ongoing therapy management.
• Provides single-use products for acute care settings.

What Industry Does ELMD Operate In?

Electromed operates in the medical device industry, specifically within the airway clearance therapy segment. This market is driven by the increasing prevalence of chronic respiratory diseases such as bronchiectasis and cystic fibrosis. The competitive landscape includes companies offering alternative airway clearance devices and therapies. Electromed differentiates itself through its focus on HFCWO technology and its SmartVest system. The global medical device market is projected to continue growing, driven by technological advancements and an aging population, providing a favorable backdrop for Electromed's growth.

Who Are ELMD's Key Customers?

• Patients with bronchiectasis.
• Patients with cystic fibrosis.
• Patients with neuromuscular disease.
• Hospitals and acute care facilities.
• Home healthcare providers.

Company Profile

Electromed, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in New Prague, US. The company is led by CEO James L. Cunniff. ELMD has traded publicly since 2010.

Return on equity for Electromed, Inc. stands at 22.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 17.0%, showing how much profit it generates from its asset base. ELMD trades at a trailing price-to-earnings ratio of 23.55, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 3.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.91 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.1%, the inverse of the P/E and a quick read on earnings relative to price.

ELMD Valuation & Market Position

With a $327M market cap, Electromed, Inc. sits in the small-cap segment of the market. Relative to its peer group, ELMD's quantitative score of 92/100 is above the peer average of 63/100.

Quarterly Financial Performance: Electromed, Inc.

Revenue for Electromed, Inc. came in at $18.6M during Q1 2026, a 1.7% contraction versus the preceding quarter. The company recorded net income of $3.0M, with diluted EPS of $0.35. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ELMD averaged $0.29 in diluted EPS.

Electromed, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 22.64 places it in the safe zone, indicating low near-term bankruptcy risk.

Electromed, Inc. has beaten Wall Street's EPS estimate in 8 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 73.0% above estimates on average.

Wall Street analysts project Electromed, Inc. revenue of about $73.6M for fiscal 2026, with EPS near $1.22.

ELMD Financials

ELMD Latest News

ELMD Analyst Consensus

ELMD MoonshotScore

Latest Electromed, Inc. Analysis

ELMD Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources